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The challenge of treating life-threatening liver disease by
transplantation of isolated hepatocytes
Management of patients with hepatic failure and liver-based
metabolic disorders is complex and expensive. Hepatic failure
results in impaired coagulation, altered consciousness and
cerebral function, a heightened risk of multiple organ system
failure, and sepsis [1]. Such manifold problems are only treatable
today and for the foreseeable future by transplantation. In fact,
whole or auxiliary partial liver transplantation is often the only
available treatment option for severe, even if transient, hepatic
failure. Patients with life-threatening liver-based metabolic
disorders similarly require organ transplantation even though
their metabolic diseases are typically the result of a single
enzyme deﬁciency, and the liver otherwise functions normally.
For all of the beneﬁts it may confer, liver transplantation is not
an ideal therapy, even for severe hepatic failure. More than
17,000 patients currently await liver transplantation in the United
States, a number that seriously underestimates the number of
patients that need treatment [2], as it has been estimated that
more than a million patients could beneﬁt from transplantation
[3]. Unfortunately, use of whole liver transplantation to treat
these disorders is limited by a severe shortage of donors and by
the risks to the recipient associated with major surgery [4].Journal of Hepatology 20
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tive to organ transplantation for the treatment of liver diseases,
and numerous studies in rodents indicate that transplants con-
sisting of isolated liver cells can correct various metabolic deﬁ-
ciencies of the liver and can reverse hepatic failure [5–17]. The
transplant procedure, which involves injection of isolated hepa-
tocytes into the liver or spleen, is far less invasive than transplan-
tation of the whole liver and could be performed on severely ill
patients with relatively low risk. In the presence of normal host
liver architecture, the transplanted cells integrate into the host
liver, providing considerable restorative potential [18]. Because
the native liver is not removed, the transplanted hepatocytes
need only improve some of the functions of the failing liver and
need not replace all hepatic functions.
Although clinical trials of hepatocyte transplantation have
demonstrated the long-term safety of the procedure, only partial
correction of metabolic disorders has been achieved, and the
degree to which donor hepatocytes have restored failing livers
has not generally been adequate to circumvent the need for organ
replacement [19–27]. While hepatocyte transplantation can be
employed safely in humans, its applicability remains limited by
a number of issues, some of which include: (1) a critical shortage
of donor organs and hepatocytes for transplantation; (2) rela-
tively poor initial and long-term hepatocyte engraftment that
limits successful treatment of chronic diseases, such as liver-
based metabolic deﬁciencies; and (3) the lack of a clinically rele-
vant animal model of acute liver failure that could be used to
accurately predict the efﬁcacy of new therapies in treating this
process.The challenge of treating acute liver failure
Several thousand cases of acute liver failure occur each year in the
UnitedStates.Approximately40%of patientswithadvancedsymp-
toms survive the acute episodewith onlymedicalmanagement. In
these cases, regeneration of the native livermakes orthotopic liver10 vol. 53 j 769–774
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transplantation unnecessary. Unfortunately, there is no effective
means to distinguish between patients who will survive without
transplantation from those who will not. Support options exist
for patients with acute renal or cardiovascular insufﬁciency, obvi-
ating the need for transplantation. Unfortunately no effective sup-
port exists for patients with liver failure.
Several factors have hindered the development of innovative
therapies for treating patients with fulminant liver failure.
Despite the availability of numerous surgical and pharmaco-
logic-based animal models of acute hepatic failure, none recapit-
ulate clinical hepatic failure to the point where the efﬁcacy of cell
transplantation or liver assist devices could be predicted in
patients [28,29]. The severity of liver dysfunction requires that
the transplanted hepatocytes function immediately, but the lack
of a clinically relevant disease model means that the number of
cells that would need to engraft and function immediately to
reverse hepatic failure remains essentially unknown. Since clini-
cal experience with auxiliary orthotopic liver transplant for acute
hepatic failure indicates that native liver recovery may take
6 months to a year, if ever [30], liver recovery in any representa-
tive animal model needs to take at least a week, if not more. The
highly variable natural history and the numerous etiologies of
acute liver failure have also made assessment of the success of
novel interventions in this patient population difﬁcult. Thus,
while extracorporeal liver assist devices and hepatocyte trans-
plantation have been applied to the treatment of acute hepatic
failure, neither approach has reliably resulted in reversal of hepa-
tic failure to the point where organ transplantation can be
avoided [31].
For hepatocyte transplantation, interpretation of its potential
has been further confounded by the wide range in the numbers
and types of cells transplanted, the sites where cells have been
infused, and spontaneous recovery rates approaching 40%
[21,27,32–39]. It is possible that enrollment of patients in a
multi-institutional standardized treatment protocol would help
delineate the potential that transplantation of hepatocytes might
have for the treatment of fulminant liver failure, and would help
identify any hurdles to its successful application. Such a
standardized protocol could focus on trying to infuse 1–2  108
viable hepatocytes per kilogram through the portal vein for
engraftment in the liver. Even this may be difﬁcult to accomplish
in a multi-center trial, as the coagulopathy associated with acute
liver failure makes access to the portal circulation challenging.
Fresh or cryopreserved hepatocytes could be considered for such
a trial, but because cryopreserved cells have been shown to
engraft less well than fresh hepatocytes (discussed later in this
review), an aliquot of each population would need to be
characterized in an identical fashion, for comparison, for in vitro
activity, plating efﬁciency, and engraftment potential in immune
deﬁcient hosts.The challenge of treating chronic liver disease resulting from
cirrhosis
Hepatocyte transplantation for end-stage liver disease is even
more problematic. Abnormalities in hepatic architecture contrib-
ute to decrease in liver function, and transplantation of hepato-
cytes into the portal vein of a cirrhotic liver can generate
severe portal hypertension. Furthermore, it is not clear that donor
hepatocytes can function for any sustained period of time to
improve hepatic failure in the abnormal cirrhotic environment770 Journal of Hepatology 201[24,40]. Animal studies suggest that transplantation into the
spleens of rats with decompensated liver cirrhosis can improve
liver function, and prolong survival [41,42]. Unfortunately, trans-
planted hepatocytes provided only transient function. Hepato-
cyte transplantation in humans with end-stage cirrhosis has not
resulted in even this level of success, but only anecdotal improve-
ment in some parameters of liver function [24,27,40,43,44]. One
explanation may be that hepatocytes were infused through the
splenic artery in clinical studies, rather than by the direct splenic
puncture approach used in the laboratory. The route of hepato-
cyte delivery into the spleen has been shown to dramatically
inﬂuence hepatocyte engraftment and function [45]. Treatment
of chronic liver failure might beneﬁt in the future from a new
technology called organ de-cellularization, where the cells from
a donor organ are removed, leaving intact the complex mixture
of structural and functional proteins that constitute the ECM. A
de-cellularized human or animal liver could serve as a biologic,
architecturally normal scaffold for transplanted cells [46,47].
The scaffold, repopulated with donor hepatocytes and non-paren-
chymal cells, might then be vascularized through the portal cir-
culation as an engineered internal auxiliary liver graft [48].
Since hepatocyte transplantation in chronic liver disease will
leave the native cirrhotic liver in place, even if successful at
improving liver function, it will still leave unresolved the man-
agement of coexisting portal hypertension and the risk of devel-
oping hepatocellular carcinoma in the native liver (Box 1).0 vol. 53 j 769–774
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The challenge of hepatocyte engraftment and treatment of liver-
based metabolic deﬁcienciesFig. 1. Partial portal vein occlusion. Laboratory studies indicate that transient
occlusion of the portal circulation can enhance donor hepatocyte engraftment by
providing a proliferation signal to donor cells, with or without conditioning of the
recipient liver by partial irradiation. Transient occlusion of the left portal venous
system is shown, allowing transplantation into the right lobe of the liver. A 6 Fr
compliant balloon is positioned in the left portal vein just beyond the bifurcation.
It is inﬂated so as to occlude the left portal vein but allows transportal infusion of
cells into the right lobe of the liver through the side port of the endovascular
sheath.In the long-term, transplanted hepatocytes appear to survive
poorly in naïve normal and in immune deﬁcient hosts
[20,49,50]. They do, however, survive well in hosts with some
forms of liver disease [51–53], and when native liver cell expan-
sion is inhibited by exogenous interventions [54,55]. These obser-
vations suggest that some homeostatic mechanism controls the
number of surviving donor hepatocytes over time. Graft survival,
thus, could be limited by a host cell survival advantage over
donor hepatocytes. This situation would be similar to that seen
in allogeneic bone marrow transplantation, where the host must
undergo a preparative regimen to create an environment condu-
cive to long-term engraftment. Preparative irradiation induces
apoptosis of host bone marrow cells and makes room for donor
cell engraftment [56], allowing macrochimerism to take place fol-
lowing infusion of donor hematopoietic stem cells. Therefore, the
use of hepatocytes for the treatment of liver-based metabolic dis-
ease may inevitably fail unless conditions can be established that
will allow the enduring survival of hepatocyte transplants, as
observed in some forms of liver damage.
Liver-directed radiation has been shown to facilitate repopu-
lation of the native liver by transplanted hepatocytes when it is
combined with a hepatic proliferation stimulus [57]. In fact, it
has been shown that providing only the hepatic proliferation
stimulus results in mild enhancement of hepatocyte engraftment
for up to 16 weeks in non-human primates [58]. This is especially
important since the number of donor cells that can be safely
transplanted into the liver at any one time via the portal vein is
small, usually less than 1% of the liver mass. Transplantation of
a larger cell mass leads to either severe portal hypertension or
translocation of cells out of the liver into the systemic circulation,
leading to embolization of cells into the lungs [7,32]. Liver-direc-
ted radiation-based preparative regimens inhibit host hepatocyte
proliferation and induce post-mitotic hepatocyte death, making
‘‘room” for donor hepatocytes to preferentially proliferate and
repopulate the irradiated host liver [57,59]. This strategy has
been employed to completely correct rodent models of heredi-
tary metabolic deﬁciencies of the liver corresponding to Cri-
gler–Najjar syndrome and primary hyperoxaluria [60,61].
Unfortunately, donor hepatocyte engraftment, survival, and
repopulation studies greater than 2 years cannot be achieved in
rodents, and pre-clinical studies in large animals would be help-
ful to conﬁrm the safety and efﬁcacy of such a strategy. For dis-
eases that may require fairly limited replacement of the host
liver by transplanted donor hepatocytes, reversible partial portal
vein embolization may result in adequate donor cell function
without the additional risks associated with conditioning the
recipient liver with irradiation, although the long-term efﬁcacy
of this strategy has not yet been demonstrated (Fig. 1).
The risk of modest doses of liver irradiation in infants using
the above strategy should be low based on the experience in
treating infants with symptomatic liver hemangiomas, and
long-term follow-up studies in Wilm’s tumor patients. From
1950s to 1980s, several reports were published concerning
infants (approximately 20) treated with radiation therapy for
symptomatic liver hemangiomas that demonstrated that radia-
tion could be safely administered from a single dose of 7 Gy to
fractionated doses of up to 50 Gy to portions of the liver. The
age of these patients ranged from 1 day to 1 year. Thus, one-thirdJournal of Hepatology 201of the normal liver volume may tolerate radiation doses as high
as 80–100 Gy without compromising normal liver function. Fur-
thermore, radiation-induced secondary liver cancer has not gen-
erally been reported in patients that receive radiation therapy
involving external beam treatment [62–66]. In the National
Wilm’s Tumor Study, where 2438 patients were followed over
14,381 person-years, only four cases of hepatocellular carcinoma
were reported in long-term follow-up, and this was only in
patients who received radiation doses P35 Gy to the right lobe
of the liver. Three out of four of those patients also received che-
motherapy, which could have contributed to the second
malignancies.
In Gunn rats, an animal model for the hyperbilirubinemia
associated with human Crigler–Najjar syndrome type I, precondi-
tioning with focused lobar irradiation to as little as 35% of the
liver mass prior to allogeneic hepatocyte transplantation results
in complete correction of the liver-based metabolic disorder
[67]. Thus, for clinical application, it should be possible to radiate
a portion of the liver in a range lower than the threshold to
induce signiﬁcant liver injury in order to augment engraftment
and replacement of the host liver with donor hepatocytes. Since
liver-directed radiation therapy can be safely administered in
the clinic using 3-D conformal and intensity-modulated radiation
therapy (IMRT) techniques, and can be easily adapted to selec-
tively irradiate part of the liver or a liver lobe without collateral
injury to surrounding structures, it should be possible to design
safe and clinically effective strategies for irradiating the host
liver, and engrafting and expanding donor hepatocytes there
(Box 2).0 vol. 53 j 769–774 771
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A major limitation to the clinical application of hepatocyte trans-
plantation has been the lack of an abundant source of human
hepatocytes. Hepatocytes are primarily obtained from livers
rejected for orthotopic liver transplantation, and unused seg-
ments of donor livers used for pediatric recipients [68]. But, these
sources do not begin to approach the potential numbers needed
to treat all patients that might potentially beneﬁt from hepato-
cyte transplantation.
One exciting new source of human hepatocytes may be livers
from non-heart-beating donors. A recent study documented that
these livers, of dubious quality for whole liver transplantation,
can generate hepatocytes with acceptable viability and quality
[69]. The primary limitation to utilizing these whole organs is
the risk of long-term biliary and vascular complications, issues
that are of little consequence when only hepatocyte yield and
viability are critical.
The impact of the scarcity of livers might be alleviated, to some
extent, by cryopreservation of isolated cells, allowing harvest and
use of hepatocytes in the absence of an immediately available
recipient. To this point, cryopreserved hepatocytes have not pro-
ven reliably capable of engrafting and functioning. Some children
with urea cycle disorders have been treated with some possible
success using cryopreserved hepatocytes [70]; however, the qual-
ity of lots of cryopreserved cells and their ability to engraft after
thawing has not been shown to be consistent by others [71–76].
Hepatocytes might also be obtained by expansion and differ-
entiation of stem cells. While this possibility has generated
enthusiasm, it remains some distance from application. Embry-
onic stem cells and induced pluripotent stem cells can be coaxed
to exhibit some functions of hepatocytes by sequential culture in
transcription and growth factors, and sorting to enrich for cells
with hepatocyte-speciﬁc characteristics [77,78]. This is difﬁcult
to accomplish in large numbers and there is still a signiﬁcant risk
of contamination of the enriched population with cells having the
potential to form tumors.
The ideal source of stemcellswouldbederived fromthe subject
to be treated. Such stem cells, referred to as induced pluripotent
stem cells (iPS cells), have been created by transducing skin cells,
or any of a number of other differentiated cell sources, with tran-
scription factors that transform them into cells that have charac-772 Journal of Hepatology 201teristics and differentiation potential nearly identical to human
embryonic stemcells (ES cells) [79,80].While there ismuch enthu-
siasm for thepotential useof stemcell-derivedhepatocytes, gener-
ation of a sufﬁcientmass of functional hepatocytes for treatment of
liver failure from autologous cells derived from iPS cells would
require a period of weeks for expansion, differentiation, selection,
and testing to exclude contamination by tumorogenic precursors,
far too long to address the problemof acute hepatic failure. In addi-
tion, autologous hepatocytes would require genetic manipulation
to treat a metabolic disease and such manipulation might result
in changes that could increase cancer risk. Thus, numerous hurdles
andunresolved risksmake this sourceof hepatocytes unlikely tobe
useful for clinical transplantation in the near future.
Finally, xenotransplantation of hepatocytes could address
many of the challenges of treating liver disorders. It is not limited
by the availability of donors, could be performed repeatedly if
needed, and may be more effective than allotransplantation for
the treatment of viral hepatitis, since xenogeneic hepatocytes do
not appear susceptible to infection by human hepatitis viruses
[81,82]. Hepatocyte xenotransplantation has been performedwith
some success in small animals with hypercholesterolemia [83]. In
addition, porcine hepatocytes have been shown to secrete albumin
for periods of months in naïve non-human primates [49], where
the enduring survival and functionof the graftswas achievedusing
a ‘‘conventional” immune suppression regimen, and did not
require theuseof donorpigs genetically engineeredwithdisrupted
synthesis of Gala1-3Gal, or expressing proteins that inhibit activa-
tionof complementbyboundantibodies [84–90]. Importantly, rats
transplanted with hepatocyte xenografts had improved indices of
coagulation, less encephalopathy, and survived longer than cir-
rhotic rats that did not receive hepatocyte xenografts [42], and
the porcine hepatocytes engrafted and corrected liver failure for
nearly 2 months without the need for immune suppression. The
hepatocyte xenografts caused the rodent recipients in liver failure
to be sensitized, but the immune response did not damage already
engrafted cells. Thus, the need for immune suppression following
hepatocyte transplantation in liver failure could be extremely
low. Development of a hepatocyte xenotransplantation program
in patientswould need to be initiatedwith caution, as the possibil-
ity of transferring an infection across species from the donor ani-
mal to man could result in a signiﬁcant public health concern.
Unfortunately, in the absence of clinically relevant models for
human liver disease in non-human primates [91,92], it has so far
not been possible to predict the extent to which a hepatocyte
xenograft would restore hepatic function in humans. Baboons
transplanted with livers derived from transgenic pigs expressing
the human complement decay accelerating factor supported the
recipient’s life for eight days, and clotting parameters reached
nearly normal levels within two days of transplantation [93].
Thus, since transplantation of isolated hepatocytes into the liver
is much less invasive than whole liver transplantation and the
immunologic barrier appears lower, hepatocyte xenotransplanta-
tion could become the preferred treatment for conditions in
which some liver function persists or can recover, such as in ful-
minant liver failure, when immediate availability of donor hepa-
tocytes could be a decisive factor in the patient’s outcome.Summary
Treatment of patients with liver disease by hepatocyte transplan-
tation has expanded dramatically over the last decade, especially0 vol. 53 j 769–774
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for treatment of patients with liver-based metabolic disorders.
While much progress has been made, full realization of its poten-
tial has not been reached. Treatment of acute liver failure has
been hampered by a number of factors, but the efﬁcacy of hepa-
tocyte transplantation in treating this entity could be better
determined through a multi-institutional trial using a uniform
and standardized treatment strategy. The barriers to treating
chronic liver failure resulting from cirrhosis are more extensive.
Novel strategies are being developed to safely precondition
patients with liver-directed radiation therapy in order to enhance
donor hepatocyte survival, long-term engraftment and improve
treatment of patients with life-threatening liver-based genetic
deﬁciencies. This work could soon be translated to the clinic.
Once hepatocyte transplantation has been shown to effectively
replace organ transplantation for a portion of patients with liver
failure and life-threatening liver metabolic diseases, it is likely
that multiple novel sources of donor hepatocytes will be devel-
oped, making cell therapy available and effective for a broad pop-
ulation of patients with liver disorders.Financial disclosure
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